Ovarian Cancer
M25-709: A Phase 2, Open-Label, Randomized, Master Protocol Dose Optimization Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations with Mirvetuximab Soravtansine in Subjects with Ovarian Cancer (FLORENZA).
- Details
ClinicalTrials.gov ID:
NCT07059845
Diagnosis Type:
NA
USOR Number:
- Address
,
P: